5 completed, 4 terminated, 1 unknown. 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 5, Terminated 4, Unknown 1 |
Follow Zilretta: new trials by email Literature Review of Zilretta trials Research Report on Zilretta
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate an Intra-Articular Injection of ZILRETTA Versus Triamcinolone Acetonide, Immediate Release in Subjects With Osteoarthritis of the Hip Zilretta, Triamcinolone Acetonide - Osteoarthritis of Hip | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 1 | 2025-07-25 | 2025-12-22 |
| Study to Evaluate Intra-articular Resiniferatoxin to Treat Moderate to Severe Pain From Knee Osteoarthritis Resiniferatoxin, Zilretta, Placebo - Osteoarthritis, Knee, Knee Osteoarthritis | Phase 2 | Unknown | Sorrento Therapeutics, Inc. | 124 | 2021-11-15 | 2023-01-17 |
| Success of Long-acting Anti-inflammatories After Anterior Cruciate Ligament and Meniscal Injury Zilretta, Placebo - Tibial Meniscus Injuries, Tibial Meniscus Tears | Phase 2 | Terminated | Austin V Stone | 1 | 2020-08-21 | 2023-07-27 |
| Study to Evaluate the Efficacy and Safety of FX006 in Patients With Glenohumeral Osteoarthritis or Shoulder Adhesive Capsulitis FX006, Normal Saline - Osteoarthritis of the Shoulder, Adhesive Capsulitis | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 19 | 2019-11-07 | 2024-01-24 |
| Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip FX006 32 mg, TAcs 40 mg - Osteoarthritis of the Shoulder, Osteoarthritis of the Hip | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 55 | 2017-12-18 | 2024-01-24 |
| Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA FX006 32 mg, TAcs 40 mg - Bilateral Knee Osteoarthritis | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 24 | 2017-12-06 | 2024-01-24 |
| Study to Assess the Effects of FX006 on Blood Glucose in Patients With OA of the Knee and Type 2 Diabetes FX006 32 mg, TCA IR 40 mg - Osteoarthritis of the Knee, Type 2 Diabetes Mellitus | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 33 | 2016-04-01 | 2024-01-24 |
| Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee FX006 32 mg, TCA IR 40 - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 81 | 2015-11-01 | 2024-01-24 |
| Proof of Concept Study Comparing FX006 to KenalogĀ®-40 in Patients With Post-Traumatic Osteoarthritis of the Knee FX006 32 mg, TCA IR 40 mg - Post-traumatic Osteoarthritis of the Knee | Phase 2 | Terminated | Pacira Pharmaceuticals, Inc | 6 | 2015-02-01 | 2024-01-24 |
| Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee FX006 32 mg, Placebo, FX006 16 mg - Osteoarthritis of the Knee | Phase 2 | Completed | Pacira Pharmaceuticals, Inc | 310 | 2014-04-01 | 2024-01-24 |
Osteoarthritis (8) · Pain (7) · Osteoarthritis, Knee (4) · Osteoarthritis, Hip (2) · Anterior Cruciate Ligament Injuries (1) · Bursitis (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Tibial Meniscus Injuries (1)
Pacira Pharmaceuticals, Inc (8) · Austin V Stone (1) · Sorrento Therapeutics, Inc. (1)
United States (10) · Canada (1)
Neil Bodick, MD (4) · Scott Kelley, MD (3) · Austin Stone, MD, PhD (1) · Martin Ferrillo (1) · Mike Royal, MD (1) · Nino Joy (1)
PMID 29088579, PMID 30203101, PMID 31662801, PMID 34350546, PMID 35258839